港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

482.357

-14.363-2.89%

漲家數：12

跌家數：18

平家數：3

市盈率：- -

高：497.296

開：496.590

低：481.390

收：496.720

成交量：7,829.28萬

成交額：21.60億

市值：3,067.82億

流通市值：2,726.46億

資料載入中...

總覽新聞資訊

B7-H3靶點ADC全球率先突破世界肺癌大會迎來中國時刻

中国新闻网

WCLC大會開幕！一文搞懂創新藥臨床指標

創新藥跌跌不休，什麼原因？華寶基金港股通創新藥ETF（520880）失守所有均線

從「產品出海」到「體系出海」，上海創新藥企復宏漢霖加速全球佈局

雲頂新耀獲董事會主席吳以芳增持2萬股每股作價約28.71港元

20%漲停效應顯現？公募調研醫藥挖出這三家雙創標的

证券市场周刊

河北一醫院工作人員先後收受商業賄賂46次，單次最大涉案金額1658萬元，持續時間最長達11年，累計涉案金額1.84億元

凱利泰子公司艾迪爾涉商業賄賂：被列為「特別嚴重失信」企業，集採衝擊、渠道失控兩頭擠壓

服貿觀瀾｜AI加速診療與製藥創新，多項創新成果集中發布

股價單邊下跌20%，存倉異動後的勁方醫藥-B(02595)何時迎來反彈時刻？

沛嘉醫療-B(09996)：GeminiOne®經導管緣對緣修復系統的註冊申請獲國家藥監局批准

董事會主席吳以芳增持雲頂新耀(01952)2萬股每股作價約28.71港元

智通财经网

創新藥將迎數據催化窗口！OS、PFS、ORR還都分不清楚？速查指南來了！收藏備用

重磅大會在前，創新藥未有起色，什麼情況？華寶基金港股通創新藥ETF（520880）失守所有均線

歸創通橋(02190)9月11日斥資111.75萬港元回購5.5萬股

康寧傑瑞製藥-B(09966.HK)9月11日斥資約97.75萬港元回購12.3萬股

再鼎醫藥(09688)授出部分受限制股份單位

榮昌生物(09995.HK)9月11日斥資215.52萬元回購1.9萬股A股

麥科田赴港上市：併購拼出的醫療器械版圖，暗藏多重隱憂

昂利康創新藥引進項目告吹：授權合作折戟背後，主業承壓研發布局遇變數

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BK1574/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":482.35672,"timestamp":1789546124622,"preClose":496.71994,"halted":0,"volume":78292841,"delay":0,"changeRate":-0.028916,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":-14.36322,"latestTime":"09-16 16:00:00","open":496.59045,"high":497.2955,"low":481.3899,"amount":2159910416.1,"amplitude":0.032021,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789608600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789522200000,1789531200000],[1789534800000,1789545600000]],"pbRate":3.69899,"peRate":164.598608,"turnoverRate":0.002939,"increases":11,"decrements":18,"flats":3,"marketCap":306781682880,"floatMarketCap":272645614616},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":497.2955,"amplitude":0.032021,"preClose":496.71994,"low":481.3899,"pbRate":"3.69899","latestPrice":482.35672,"volume":78292841,"delay":0,"open":496.59045,"prevYearClose":556.26263,"prevWeekClose":483.155,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":512.388,"twentyDayClose":492.831,"sixtyDayClose":437.952,"secType":"PLATE","market":"HK","turnoverRate":0.002939,"peRate":164.598608,"marketCap":306781682880,"floatMarketCap":272645614616,"timestamp":1789546124622,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":12,"down":18,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667682589","title":"B7-H3靶點ADC全球率先突破 世界肺癌大會迎來中國時刻","url":"https://stock-news.laohu8.com/highlight/detail?id=2667682589","media":"中国新闻网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667682589?lang=zh_tw&edition=fundamental","pubTime":"2026-09-13 20:11","pubTimestamp":1789301465,"startTime":"0","endTime":"0","summary":"9月13日，韩国首尔，世界肺癌大会(WCLC)主席论坛。中山大学肿瘤防治中心张力教授分享了B7-H3抗体偶联药物依康坦博妥塔单抗(Tam-Peli，代号YL201)对比盐酸托泊替康用于治疗复发性小细胞肺癌的Ⅲ期注册研究TAISHAN-302成果，这是全球范围内以B7-H3为靶点的ADC首次公布Ⅲ期临床研究数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609133872861815.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609133872861815.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["KURE","IBBQ","BK1161","MEDX","LNGR","06978","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667272684","title":"WCLC大會開幕！一文搞懂創新藥臨床指標","url":"https://stock-news.laohu8.com/highlight/detail?id=2667272684","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667272684?lang=zh_tw&edition=fundamental","pubTime":"2026-09-13 19:26","pubTimestamp":1789298760,"startTime":"0","endTime":"0","summary":"9月12日，2026年WCLC正式开幕，康方生物、石药集团、科伦博泰生物等诸多创新药龙头公司公布旗下核心产品临床数据。FDA加速批准程序允许基于替代终点批准药物，但上市后需完成确证性试验。FDA规定，提交后30天内若无异议，IND自动生效。文中提及个股在恒生港股通创新药精选指数中的权重占比情况见配图。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-13/doc-inirsuvw4447257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","IBBQ","BK1161","06978","159992","LNGR","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667684274","title":"創新藥跌跌不休，什麼原因？華寶基金港股通創新藥ETF（520880）失守所有均線","url":"https://stock-news.laohu8.com/highlight/detail?id=2667684274","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667684274?lang=zh_tw&edition=fundamental","pubTime":"2026-09-13 19:25","pubTimestamp":1789298700,"startTime":"0","endTime":"0","summary":"100%创新药研发标的——港股通创新药ETF华宝失守所有均线，重仓A股创新药的药ETF华宝标的指数日K、周K双双五连阴。图：港股通创新药ETF华宝近6月日K走势如何看待创新药本轮调整？低位埋伏创新药，关注两大投资工具：港股通创新药ETF华宝：紧密跟踪恒生港股通创新药精选指数，100%布局创新药研发类公司，前十大权重股占比超七成，龙头属性突出，底层资产是港股，高弹性、T+0。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-13/doc-inirsuvy5397470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBQ","BK1574","FLHK","159316","520880","BK1161","MEDX","06978","LNGR","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667681787","title":"從「產品出海」到「體系出海」，上海創新藥企復宏漢霖加速全球佈局","url":"https://stock-news.laohu8.com/highlight/detail?id=2667681787","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667681787?lang=zh_tw&edition=fundamental","pubTime":"2026-09-13 17:19","pubTimestamp":1789291195,"startTime":"0","endTime":"0","summary":"日前，上海创新药企复宏汉霖举办2026年开放日活动，围绕全球化布局、生物类似药商业化、创新研发及临床开发等话题披露最新进展。复宏汉霖执行董事、首席执行官朱俊博士介绍，截至目前，复宏汉霖已有4款产品获美国食品药品监督管理局（FDA）批准、5款获欧盟（EC）批准、8款获中国国家药品监督管理局（NMPA）批准，产品已惠及全球超过110万名患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609133872844911.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609133872844911.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LNGR","BK1574","IBBQ","HK0000165453.HKD","HK0000306685.HKD","HK0000320264.USD","HK0000320223.HKD","HK0000306701.USD","BK1161","159992","06978","MEDX","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667860876","title":"雲頂新耀獲董事會主席吳以芳增持2萬股 每股作價約28.71港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667860876","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667860876?lang=zh_tw&edition=fundamental","pubTime":"2026-09-13 13:53","pubTimestamp":1789278780,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端香港联交所最新数据显示，9月10日，董事会主席吴以芳增持云顶新耀（01952）2万股，每股作价28.7065港元，总金额约为57.41万港元。增持后最新持股数目约为218.02万股，最新持股比例为0.62%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-09-13/doc-inirscya7885197.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EWH","01952","BK1161","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667852816","title":"20%漲停效應顯現？公募調研醫藥挖出這三家雙創標的","url":"https://stock-news.laohu8.com/highlight/detail?id=2667852816","media":"证券市场周刊","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667852816?lang=zh_tw&edition=fundamental","pubTime":"2026-09-13 11:11","pubTimestamp":1789269060,"startTime":"0","endTime":"0","summary":"Wind资讯显示，从6月以来公募医药基金经理的调研看，比如义翘神州、赛科希德、兴齐眼药等等。Wind资讯显示，本次调研总共有20家机构参与，其中包括了10家券商、5家私募、3家投资机构和2家公募。公司产品不直接用于临床治疗，主要是作为工具试剂，用于支持科研机构和生物医药企业的研究工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/roll/2026-09-13/doc-inirrxsh4698780.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","09939","BK1574","159938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667683005","title":"河北一醫院工作人員先後收受商業賄賂46次，單次最大涉案金額1658萬元，持續時間最長達11年，累計涉案金額1.84億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667683005","media":"大象新闻","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667683005?lang=zh_tw&edition=fundamental","pubTime":"2026-09-13 09:18","pubTimestamp":1789262280,"startTime":"0","endTime":"0","summary":"继上海某科贸商行涉支架球囊行贿案公开曝光河北医科大学第二医院“每条支架收5000元回扣”后，仅2025年下半年，该院又涉及9件司法刑事判决。该医院工作人员先后收受商业贿赂46次，单次最大涉案金额1658万元，持续时间最长达11年，累计涉案金额1.84亿元。分析发现，超过30家医药企业长期对该医院工作人员行贿。河北祥恩医疗器械贸易有限公司为向河北医科大学第二医院销售价格虚高的医疗耗材，累计向该医院工作人员行贿2064万元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-13/doc-inirrtkk4766738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["PTH","AGNG","RSPH","HART","IEIH","BK1583","BK1574","BK1515","LGHT","LNGR","MDEV","09939","BK1161","GDOC","MEDX","BK1100","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666504386","title":"凱利泰子公司艾迪爾涉商業賄賂：被列為「特別嚴重失信」企業，集採衝擊、渠道失控兩頭擠壓","url":"https://stock-news.laohu8.com/highlight/detail?id=2666504386","media":"蓝鲸财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666504386?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 21:10","pubTimestamp":1789218656,"startTime":"0","endTime":"0","summary":"蓝鲸新闻向凯利泰方面求证具体涉案信息，截至发稿尚未收到回复。通过检索公开权威信息发现，除了此次事件，近年来，艾迪尔屡次被曝涉嫌商业贿赂。艾迪尔母公司凯利泰同样多次涉及商业贿赂事件。因为一旦被评定为“特别严重失信”，很可能会失去医保报销市场，对企业发展会带来巨大冲击。不过目前来看，作为名单中7家被评为“特别严重失信”的企业之一，艾迪尔尚未发表致歉声明。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789198644422913532","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["300326","MEDX","BK1583","PTH","09996","HART","BK0251","RSPH","AGNG","GDOC","LGHT","BK1100","MDEV","IEIH","LNGR","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666350104","title":"服貿觀瀾｜AI加速診療與製藥創新，多項創新成果集中發布","url":"https://stock-news.laohu8.com/highlight/detail?id=2666350104","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666350104?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 20:43","pubTimestamp":1789217000,"startTime":"0","endTime":"0","summary":"9月12日，2026年服贸会“智能+医疗健康”论坛在北京首钢园举行。本次论坛以“智能赋能医疗健康质量发展”为主题，聚焦人工智能在医疗领域的深度应用与产业变革。论坛上同步落地两大重磅平台载体，AI+精准诊疗与AI+生物医药制造领域的多项阶段性创新成果也集中亮相，展示了北京在推动人工智能与医疗健康深度融合上的前沿探索与实践。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609123872755023.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609123872755023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ARTY","01477","BK1191","BK1574","VTHR","AIPO","AGIX","QTOC","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666450157","title":"股價單邊下跌20%，存倉異動後的勁方醫藥-B(02595)何時迎來反彈時刻？","url":"https://stock-news.laohu8.com/highlight/detail?id=2666450157","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666450157?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 19:27","pubTimestamp":1789212439,"startTime":"0","endTime":"0","summary":"8月26日以来，劲方医药-B股价走出了一轮单边下跌行情，13个交易日内累跌幅度近20%。在板块回调趋势下，导致劲方医药同期股价跑输板块的原因或在于即将到来的公司大股东减持。盘面表现上，劲方医药近日股价累跌近20%的直接原因显然在于9月19日的新一轮解禁潮。而对劲方医药股价构成实际短期负面压力的原因则在于一笔存仓异动。香港联交所资料显示，9月3日，劲方医药)出现存仓异动，存仓市值总计19.55亿港元，占比19.65%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","BK1515","02595","159938","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666270375","title":"沛嘉醫療-B(09996)：GeminiOne®經導管緣對緣修復系統的註冊申請獲國家藥監局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2666270375","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666270375?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 21:38","pubTimestamp":1789133924,"startTime":"0","endTime":"0","summary":"智通财经APP讯，沛嘉医疗-B(09996)发布公告，公司自主研发的GeminiOne®经导管缘对缘修复(“TEER”)系统(“ GeminiOne®”)近期已获中华人民共和国国家药品监督管理局(“国家药监局”)批准其注册申请。GeminiOne®获批标志着集团正式进入二尖瓣反流的商业化治疗领域，并代表集团在主动脉瓣狭窄及主动脉瓣反流治疗既有布局的基础上，进一步显著扩充其经导管瓣膜治疗产品组合。关于 GeminiOne®之EU MDR CE标志注册申请及美国早期可行性研究。GeminiOne®之 EU MDR CE标志注册申请已提交，而美国早期可行性研究现正进行中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495248.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","09996","BK1100","159891","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666524123","title":"董事會主席吳以芳增持雲頂新耀(01952)2萬股 每股作價約28.71港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666524123","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666524123?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 19:22","pubTimestamp":1789125762,"startTime":"0","endTime":"0","summary":"9月10日，董事会主席吴以芳增持云顶新耀(01952)2万股，每股作价28.7065港元，总金额约为57.41万港元。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260911/20260911192313_55668.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260911/20260911192313_55668.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495163.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","EWH","01952","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666798529","title":"創新藥將迎數據催化窗口！OS、PFS、ORR還都分不清楚？速查指南來了！收藏備用","url":"https://stock-news.laohu8.com/highlight/detail?id=2666798529","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666798529?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 19:22","pubTimestamp":1789125720,"startTime":"0","endTime":"0","summary":"创新药重磅提示！就在周六，2026年WCLC将正式开幕，康方生物、石药集团、科伦博泰生物等诸多创新药龙头公司将公布旗下核心产品临床数据。III期达到终点，意味着获批概率大幅提升，属于实质性大利好。临床试验中通常报告“中位OS”，即50%患者存活的时间。FDA加速批准程序允许基于替代终点批准药物，但上市后需完成确证性试验。FDA规定，提交后30天内若无异议，IND自动生效。以优效性为目标的头对头试验证据级别最高。权重数据截至2026.8.31。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-11/doc-inirnhrw8907408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","LNGR","06978","ORR","IBBQ","BK1574","MEDX","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666529140","title":"重磅大會在前，創新藥未有起色，什麼情況？華寶基金港股通創新藥ETF（520880）失守所有均線","url":"https://stock-news.laohu8.com/highlight/detail?id=2666529140","media":"新浪基金","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666529140?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 19:17","pubTimestamp":1789125420,"startTime":"0","endTime":"0","summary":"100%创新药研发标的——港股通创新药ETF华宝失守所有均线，重仓A股创新药的药ETF华宝标的指数日K、周K双双五连阴。图：港股通创新药ETF华宝近6月日K走势如何看待创新药本轮调整？低位埋伏创新药，关注两大投资工具：港股通创新药ETF华宝：紧密跟踪恒生港股通创新药精选指数，100%布局创新药研发类公司，前十大权重股占比超七成，龙头属性突出，底层资产是港股，高弹性、T+0。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-11/doc-inirnhry5675751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","BK1574","FLHK","520880","159316","LNGR","MEDX","BK1161","IBBQ","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666525663","title":"歸創通橋(02190)9月11日斥資111.75萬港元回購5.5萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666525663","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666525663?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 18:17","pubTimestamp":1789121832,"startTime":"0","endTime":"0","summary":"智通财经APP讯，归创通桥(02190)发布公告，于2026年9月11日，该公司斥资111.75万港元回购5.5万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495093.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1583","BK1587","BK1100","02190"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666525574","title":"康寧傑瑞製藥-B(09966.HK)9月11日斥資約97.75萬港元回購12.3萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666525574","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666525574?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 18:14","pubTimestamp":1789121672,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09966","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666525377","title":"再鼎醫藥(09688)授出部分受限制股份單位","url":"https://stock-news.laohu8.com/highlight/detail?id=2666525377","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666525377?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 18:12","pubTimestamp":1789121556,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)公布，公司于2026年9月8日(美国东部时间)根据2024年股权激励计划授出部分受限制股份单位，涉及15.6万股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495085.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4548","BK1574","BK4526","BK1588","BK1161","BK4585","ZLAB","BK4139","09688","BK4531","LU2488822045.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666406725","title":"榮昌生物(09995.HK)9月11日斥資215.52萬元回購1.9萬股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666406725","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666406725?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 17:06","pubTimestamp":1789117581,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02827","03188","83130","83188","09995","BK1161","02846","BK1583","BK1147","BK1574","07233","03130","LU1969619763.USD","LU2328871848.SGD","82846"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666938544","title":"麥科田赴港上市：併購拼出的醫療器械版圖，暗藏多重隱憂","url":"https://stock-news.laohu8.com/highlight/detail?id=2666938544","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666938544?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 15:35","pubTimestamp":1789112100,"startTime":"0","endTime":"0","summary":"近日，麦科田正式开启港股全球发售。盈利脆弱性在 2026 年一季度进一步暴露，上市前夕再度出现 252.7 万元亏损。靠并购快速拼出业务版图的麦科田，即将站上港股资本市场。对于麦科田而言，如何完成并购资产的深度整合、夯实自主研发实力、化解商誉与渠道危机，将决定它能否从并购拼凑的企业，蜕变为具备内生竞争力的医疗器械公司。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-09-11/doc-inirmvzx5385233.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09996","BK1583","HART","LNGR","XMMO","RSPH","BK1100","BK1574","GDOC","LGHT","CALF","BK4585","IEIH","PTH","AGNG","02041","KCE","BK4588","MDEV","MEDX","159883","MYLD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666544925","title":"昂利康創新藥引進項目告吹：授權合作折戟背後，主業承壓研發布局遇變數","url":"https://stock-news.laohu8.com/highlight/detail?id=2666544925","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666544925?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 15:35","pubTimestamp":1789112100,"startTime":"0","endTime":"0","summary":"9 月 6 日，昂利康发布公告宣布终止与亚飞生物、亲合力的 IMD\u001e1005肿瘤抗体药物授权许可合作。02主业盈利出现下滑，创新转型面临双重考验创新药引进受挫的同时，昂利康主业经营已经显现压力。原料药业务是昂利康的基本盘，业绩下滑说明核心主业易受行业周期、市场供需波动冲击，自身抗周期能力有待加强。未来昂利康既要稳固原料药基本盘，也需要平衡好资金投入与管线风险，审慎推进授权引进类项目。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-09-11/doc-inirmvzx5384750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","159992","MEDX","IBBQ","BK1161","LNGR","002940","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":17,"pageCount":6,"totalSize":329,"code":"91000000","status":"200"}]}}